Xspray Pharma
Develops improved cancer drugs (PKIs) using a patented amorphous formulation technology.
XSPRAY | ST
Overview
Corporate Details
- ISIN(s):
- SE0009973563 (+3 more)
- LEI:
- 549300NGRQCNZ3X4L157
- Country:
- Sweden
- Address:
- Scheeles väg 2, 171 65 Solna
- Website:
- https://xspraypharma.com/
- Sector:
- Manufacturing
Description
Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-05 08:00 | Swedish | 458.5 KB | |||
| 2025-11-05 08:00 | English | 460.3 KB | |||
| 2025-10-10 10:00 |
Xspray Pharmas valberedning inför årsstämman 2026
|
Swedish | 44.7 KB | ||
| 2025-10-10 10:00 |
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2026
|
English | 44.5 KB | ||
| 2025-10-08 02:40 |
Xspray Pharma uppdaterar om FDA-processen för Dasynoc – anmärkningar hos kontra…
|
Swedish | 45.4 KB | ||
| 2025-10-08 02:40 |
Xspray Pharma provides update on the FDA process for Dasynoc – observations at …
|
English | 45.1 KB | ||
| 2025-09-30 15:55 |
Nytt antal aktier och röster i Xspray Pharma efter nyemission
|
Swedish | 42.5 KB | ||
| 2025-09-30 15:55 |
New number of shares and votes in Xspray Pharma after new share issue
|
English | 42.2 KB | ||
| 2025-09-11 08:00 |
Xsprays företrädesemission övertecknad –övertilldelningsemission utökad och ful…
|
Swedish | 62.2 KB | ||
| 2025-09-11 08:00 |
Xspray’s rights issue oversubscribed – over-allotment issue increased and fully…
|
English | 62.2 KB | ||
| 2025-08-26 13:10 |
Första dag för handel i teckningsrätter och BTAs flyttad till 27 augusti
|
Swedish | 57.3 KB | ||
| 2025-08-26 13:10 |
First day of trading in subscription rights and BTAs moved to August 27
|
English | 56.6 KB | ||
| 2025-08-25 16:55 |
Xspray publishes disclosure document regarding rights issue
|
English | 58.3 KB | ||
| 2025-08-25 16:55 |
Xspray offentliggör informationsdokument avseende företrädesemission
|
Swedish | 58.6 KB | ||
| 2025-08-25 16:45 |
Xspray receives additional subscription undertakings of SEK 20 million in the o…
|
English | 60.6 KB |
Automate Your Workflow. Get a real-time feed of all Xspray Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xspray Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xspray Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-10 | Anders Ekblom | Other | Buy | 168,000 | 4,998,000.00 SEK |
| 2024-06-04 | Ribbskottet AB Anders Bladh | Other | Buy | 1,958 | 145,655.62 SEK |
| 2024-06-03 | Anders Bladh, Ribbskottet | Other | Buy | 3,042 | 225,077.58 SEK |
| 2024-05-29 | Per Andersson | Other | Buy | 51,749 | 489,545.54 SEK |
| 2024-05-27 | Per Andersson | Other | Sell | 9,950 | 687,545.00 SEK |
| 2024-05-16 | Anders Bladh | Other | Buy | 10,000 | 503,500.00 SEK |
| 2024-05-02 | Maris Hartmanis | Other | Other | 2,385 | 95,400.00 SEK |
| 2024-05-02 | Christine Lind | Other | Other | 666 | 26,640.00 SEK |
| 2024-05-02 | Anders Ekblom | Other | Other | 500 | 20,000.00 SEK |
| 2024-03-05 | Robert Molander | Other | Buy | 5,000 | 20,000.00 USD |
Peer Companies
